文献速递消化道肿瘤放疗放疗物理与技术

LAP07三期试验:局部晚期胰腺癌放疗质量与毒性及生存的关系

Investigation of Relation of Radiation Therapy Quality With Toxicity and Survival in LAP07 Phase 3 Trial for Locally Advanced Pancreatic Carcinoma.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2021-02-06

LAP07随机研究评估局部晚期胰腺癌经4个月诱导化疗控制后,放化疗对比继续化疗是否延长总生存。本分析探讨放疗指南依从性对生存和毒性的影响。

核心结论

  • 放疗重大偏差与总生存较差呈趋势相关,但无进展生存无差异。
  • 因重大偏差率低,其对LAP07试验结果的影响可能可忽略。

研究设计与样本

  • LAP07为国际多中心随机III期试验,本分析为预设次要终点分析。
  • 方案含详细书面放疗指南,参与机构先完成基准病例,重大偏差中心须改进后方可入组。
  • 试验中放疗质量保证为中央审查治疗计划及剂量体积直方图,依从性分为方案合规、轻微偏差和重大偏差。
  • 442例入组患者中133例随机至放化疗组,117例可评估放疗质量。

主要发现

  • 117例可评估患者中,38.5%方案合规,43.6%轻微偏差,17.9%重大偏差。
  • 最常见方案违背为剂量分布不均匀。

关键数值与推荐

  • 放疗指南依从性分级:方案合规、轻微偏差、重大偏差。

临床怎么用

  • 局部晚期胰腺癌放化疗应严格遵循放疗指南,中央审查治疗计划和剂量体积直方图可识别偏差。
  • 出现重大偏差时需关注总生存可能较差及恶心增加的风险。

局限性

  • 重大偏差率低,其对试验结果的影响可能可忽略。
  • 放疗质量分析仅纳入117例可评估患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The LAP07 multicenter randomized study assessed whether chemoradiation therapy increases overall survival versus continuation chemotherapy in patients whose locally advanced pancreatic cancer was controlled after 4 months of induction chemotherapy. This analysis investigated whether failure to adhere to radiation therapy (RT) guidelines influenced survival and toxicity. METHODS AND MATERIALS: This is a planned analysis of secondary objectives in the framework of a randomized international phase 3 trial. The protocol included detailed written RT guidelines. All participating institutions undertook an initial benchmark case to check adherence to protocol guidelines. Centers with major deviation were not allowed to include patients until they achieved a significant improvement and rigorously followed the guidelines. On-trial RT quality assurance consisted of a central review of treatment plan with dose-volume histograms for each patient. Adherence to guidelines was graded as per protocol (PP), minor deviation (MiD), or major deviation (MaD). RESULTS: Fifty-seven benchmark cases were evaluated, 26% were classified as PP, 60% were MiD, and 14% were MaD. Among the 442 included patients, 133 patients were randomized in the chemoradiation therapy arm, and 117 patients were assessable for RT quality analysis. RT quality was graded as PP in 38.5% of patients, MiD in 43.6% of patients, and MaD in 17.9% of patients. The most frequent protocol violations were dose distribution heterogeneities. Median overall survival was 17 months with PP and MiD versus 13.4 months with MaD (hazard ratio [HR], 1.63; 95% confidence interval [CI], 0.99-2.71; P = .055). There was no difference in terms of progression-free survival (HR, 1.09; 95% CI, 0.66-1.8; P = .72). Patients with MaD had more nausea than patients treated PP or with MiD (P = .0045). CONCLUSIONS: MaD was associated with a trend for worst survival. There was no difference in terms of progression-free survival. Because of the low rate of major deviations, their effects on the LAP07 trial results may be negligeable.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Giraud P, Racadot S, Vernerey D, et al. Investigation of Relation of Radiation Therapy Quality With Toxicity and Survival in LAP07 Phase 3 Trial for Locally Advanced Pancreatic Carcinoma. Int J Radiat Oncol Biol Phys. 2021. PMID: 33561507. doi:10.1016/j.ijrobp.2021.01.055

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。